Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Enterprise Value (EV) on June 03, 2024: USD 25.92 M

Iterum Therapeutics PLC Enterprise Value (EV) is USD 25.92 M on June 03, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.
  • Iterum Therapeutics PLC 52-week high Enterprise Value (EV) is USD 27.41 M on May 13, 2024, which is 5.75% above the current Enterprise Value (EV).
  • Iterum Therapeutics PLC 52-week low Enterprise Value (EV) is USD -210.03 K on February 29, 2024, which is -100.81% below the current Enterprise Value (EV).
  • Iterum Therapeutics PLC average Enterprise Value (EV) for the last 52 weeks is USD 15.44 M.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email